Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Fulacimstat is an inhibitor of chymase (IC50s = 4 and 3 nM for the human and hamster enzyme, respectively).1 It reduces cardiac fibrosis induced by the β1-adrenergic receptor (B1-AR) and β2-AR agonist isoprenaline (isoproterenol; Item No. 15592) in hamsters when administered at doses of 1, 3, and 10 mg/kg. Fulacimstat (2 and 5 mg/kg per day) inhibits microembolism-induced decreases in left ventricular ejection fraction and increases in left ventricular end-systolic volume, decreases in plasma levels of N-terminal pro-brain natriuretic peptide (nt-proBNP), TGF-β1, and TNF-α, as well as the levels of interstitial fibrosis and the cross-sectional area of myocytes, a measure of myocyte hypertrophy, in a coronary microembolism-induced canine model of heart failure.2
WARNING This product is not for human or veterinary use.
1. Abstract 13624: A novel chymase inhibitor BAY 1142524 reduces fibrosis and improves cardiac function after myocardial infarction in hamster. Circulation 136(suppl. 1), A13624 (2017).
2. Abstract 11585: Long-